{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:25:07Z","timestamp":1791872707188,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006098","name":"Radiological Society of North America","doi-asserted-by":"publisher","award":["Research Scholar Grant"],"award-info":[{"award-number":["Research Scholar Grant"]}],"id":[{"id":"10.13039\/100006098","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sirtex Medical Ltd","award":["Investigator Initiated Study"],"award-info":[{"award-number":["Investigator Initiated Study"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is an increasing body of evidence indicating Y90 dose thresholds for tumor response and treatment-related toxicity. These thresholds are poorly studied in resin Y90, particularly in hepatocellular carcinoma (HCC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the efficacy of prospective voxel-based dosimetry for predicting treatment response and adverse events (AEs) in patients with HCC undergoing resin-based Y90 radioembolization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This correlative study was based on a prospective single-arm clinical trial (NCT04172714), which evaluated the efficacy of low\/scout (555\u00a0MBq) activity of resin-based Y90 for treatment planning. Partition model was used with goal of tumor dose (TD)\u2009&gt;\u2009200\u00a0Gy and non-tumoral liver dose (NTLD)\u2009&lt;\u200970\u00a0Gy for non-segmental therapies. Single compartment dose of 200\u00a0Gy was used for segmentectomies. Prescribed Y90 activity minus scout activity was administered for therapeutic Y90 followed by Y90-PET\/CT. Sureplan\u00ae (MIM Software, Cleveland, OH) was used for dosimetry analysis. Treatment response was evaluated at 3 and 6\u00a0months. Receiver operating characteristic curve determined TD response threshold for objective response (OR) and complete response (CR) as well as non-tumor liver dose (NTLD) threshold that predicted AEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200930 patients were treated with 33 tumors (19 segmental and 14 non-segmental). One patient died before the first imaging, and clinical follow-up was excluded from this analysis. Overall, 26 (81%) of the tumors had an OR and 23 (72%) had a CR. A mean TD of 253\u00a0Gy predicted an OR with 92% sensitivity and 83% specificity (area under the curve (AUC\u2009=\u20090.929,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). A mean TD of 337\u00a0Gy predicted a CR with 83% sensitivity and 89% specificity (AUC\u2009=\u20090.845,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). A mean NTLD of 81 and 87\u00a0Gy predicted grade 3 AEs with 100% sensitivity and 100% specificity in the non-segmental cohort at 3- and 6-month post Y90, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with HCC undergoing resin-based Y90, there are dose response and dose toxicity thresholds directly affecting outcomes.<\/jats:p>\n                    <jats:p>Clinical trial number: NCT04172714.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-023-06111-9","type":"journal-article","created":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T23:23:44Z","timestamp":1673997824000},"page":"1743-1752","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Voxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization: a prospective, single-arm study"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4569-2720","authenticated-orcid":false,"given":"Nima","family":"Kokabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linzi","family":"Arndt-Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Brandon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ila","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Davarpanahfakhr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Galt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Bercu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mircea","family":"Cristescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Cheenu","family":"Kappadath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,18]]},"reference":[{"issue":"5","key":"6111_CR1","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1055\/s-0040-1720954","volume":"37","author":"A Villalobos","year":"2020","unstructured":"Villalobos A, et al. Yttrium-90 radioembolization dosimetry: what trainees need to know. Semin Intervent Radiol. 2020;37(5):543\u201354.","journal-title":"Semin Intervent Radiol"},{"issue":"1","key":"6111_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","volume":"6","author":"E Garin","year":"2021","unstructured":"Garin E, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(1):17\u201329.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"6111_CR3","doi-asserted-by":"crossref","unstructured":"Kim E, et al. Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study. Lancet Gastroenterol Hepatol.\u00a02022;7(9):843\u201350.","DOI":"10.1016\/S2468-1253(22)00091-7"},{"key":"6111_CR4","doi-asserted-by":"crossref","unstructured":"Lam M, et al. A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study.\u00a0Eur J Nucl Med Mol Imaging. 2022;49(10):3340\u201352.","DOI":"10.1007\/s00259-022-05774-0"},{"key":"6111_CR5","doi-asserted-by":"crossref","unstructured":"Gabr A, et al. Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants. Eur J Nucl Med Mol Imaging. 2021;48(2):580\u20133.","DOI":"10.1007\/s00259-020-04976-8"},{"issue":"4","key":"6111_CR6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1055\/s-0041-1732323","volume":"38","author":"LA Webster","year":"2021","unstructured":"Webster LA, et al. Standard Radiation dosimetry models: what interventional radiologists need to know. Semin Intervent Radiol. 2021;38(4):405\u201311.","journal-title":"Semin Intervent Radiol"},{"issue":"3","key":"6111_CR7","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1007\/s00270-012-0481-2","volume":"36","author":"LE Moreno-Luna","year":"2013","unstructured":"Moreno-Luna LE, et al. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2013;36(3):714\u201323.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"2","key":"6111_CR8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1053\/j.gastro.2010.10.049","volume":"140","author":"R Salem","year":"2011","unstructured":"Salem R, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterol. 2011;140(2):497-507.e2.","journal-title":"Gastroenterol"},{"issue":"5","key":"6111_CR9","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1148\/rg.2015140314","volume":"35","author":"JC Camacho","year":"2015","unstructured":"Camacho JC, et al. (90)Y Radioembolization: multimodality imaging pattern approach with angiographic correlation for optimized target therapy delivery. Radiographics. 2015;35(5):1602\u201318.","journal-title":"Radiographics"},{"key":"6111_CR10","doi-asserted-by":"crossref","unstructured":"Kokabi N, et al. Accuracy and safety of scout dose resin yttrium-90 microspheres for radioembolization therapy treatment planning: a prospective single-arm clinical trial. J Vasc Interv Radiol. 2022;33(12):1578\u201387.","DOI":"10.1016\/j.jvir.2022.08.027"},{"key":"6111_CR11","unstructured":"Kokabi N, S I, Mir D, Schuster DM, Lee JS, Kappadath S, Risk B, Galt JR. Evaluation of utility of low dose yttrium-90 for radioembolization treatment planning using SPECT\/CT and PET\/CT-a phantom study. Eur J Nucl Med Mol Imaging.\u00a02019;46(Suppl 1):S259."},{"issue":"2","key":"6111_CR12","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s00270-020-02638-8","volume":"44","author":"M Elsayed","year":"2021","unstructured":"Elsayed M, et al. Comparison of Tc-99m MAA planar versus SPECT\/CT imaging for lung shunt fraction evaluation prior to Y-90 radioembolization: are we overestimating lung shunt fraction? Cardiovasc Intervent Radiol. 2021;44(2):254\u201360.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"1","key":"6111_CR13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13550-018-0402-8","volume":"8","author":"JD Allred","year":"2018","unstructured":"Allred JD, et al. The value of 99mTc-MAA SPECT\/CT for lung shunt estimation in 90Y radioembolization: a phantom and patient study. EJNMMI Res. 2018;8(1):50.","journal-title":"EJNMMI Res"},{"issue":"supplement 1","key":"6111_CR14","first-page":"265","volume":"60","author":"H Gill","year":"2019","unstructured":"Gill H, et al. 99mTc-MAA SPECT\/CT imaging for quantitative assessment of lung shunt fraction prior to 90Y transarterial radioembolization. J Nucl Med. 2019;60(supplement 1):265\u2013265.","journal-title":"J Nucl Med"},{"issue":"9","key":"6111_CR15","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.2967\/jnumed.117.205203","volume":"59","author":"H Dittmann","year":"2018","unstructured":"Dittmann H, et al. A prospective study of quantitative SPECT\/CT for evaluation of lung shunt fraction before SIRT of liver tumors. J Nucl Med. 2018;59(9):1366\u201372.","journal-title":"J Nucl Med"},{"key":"6111_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13550-014-0033-7","volume":"4","author":"YH Kao","year":"2014","unstructured":"Kao YH, et al. Personalized predictive lung dosimetry by technetium-99m macroaggregated albumin SPECT\/CT for yttrium-90 radioembolization. EJNMMI Res. 2014;4:33.","journal-title":"EJNMMI Res"},{"issue":"5","key":"6111_CR17","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1002\/mp.13444","volume":"46","author":"NM Maughan","year":"2019","unstructured":"Maughan NM, et al. Validation of post-treatment PET-based dosimetry software for hepatic radioembolization of yttrium-90 microspheres. Med Phys. 2019;46(5):2394\u2013402.","journal-title":"Med Phys"},{"issue":"1015","key":"6111_CR18","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1259\/bjr\/33524085","volume":"85","author":"YH Kao","year":"2012","unstructured":"Kao YH, et al. Yttrium-90 internal pair production imaging using first generation PET\/CT provides high-resolution images for qualitative diagnostic purposes. Br J Radiol. 2012;85(1015):1018\u20139.","journal-title":"Br J Radiol"},{"key":"6111_CR19","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejmp.2019.09.236","volume":"68","author":"SP Kim","year":"2019","unstructured":"Kim SP, et al. A guide to (90)Y radioembolization and its dosimetry. Phys Med. 2019;68:132\u201345.","journal-title":"Phys Med"},{"issue":"1","key":"6111_CR20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/2191-219X-3-56","volume":"3","author":"YH Kao","year":"2013","unstructured":"Kao YH, et al. Post-radioembolization yttrium-90 PET\/CT - part 1: diagnostic reporting. EJNMMI Res. 2013;3(1):56.","journal-title":"EJNMMI Res"},{"issue":"2","key":"6111_CR21","doi-asserted-by":"publisher","first-page":"e55742","DOI":"10.1371\/journal.pone.0055742","volume":"8","author":"M Elschot","year":"2013","unstructured":"Elschot M, et al. Quantitative comparison of PET and bremsstrahlung SPECT for imaging the in vivo yttrium-90 microsphere distribution after liver radioembolization. PLoS One. 2013;8(2):e55742.","journal-title":"PLoS One"},{"issue":"8","key":"6111_CR22","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.jvir.2013.04.018","volume":"24","author":"SA Padia","year":"2013","unstructured":"Padia SA, et al. Comparison of positron emission tomography and bremsstrahlung imaging to detect particle distribution in patients undergoing yttrium-90 radioembolization for large hepatocellular carcinomas or associated portal vein thrombosis. J Vasc Interv Radiol. 2013;24(8):1147\u201353.","journal-title":"J Vasc Interv Radiol"},{"issue":"11","key":"6111_CR23","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1097\/MNM.0b013e328364aa4b","volume":"34","author":"AA Zade","year":"2013","unstructured":"Zade AA, et al. 90Y microsphere therapy: does 90Y PET\/CT imaging obviate the need for 90Y Bremsstrahlung SPECT\/CT imaging? Nucl Med Commun. 2013;34(11):1090\u20136.","journal-title":"Nucl Med Commun"},{"key":"6111_CR24","unstructured":"US Department of Health and Human Services. Common terminology criteria for adverse events. Version 5.0. Published November 27, 2017. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf (2020). Accessed 20 Aug\u00a02022."},{"issue":"6","key":"6111_CR25","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.jhep.2017.01.012","volume":"66","author":"R Lencioni","year":"2017","unstructured":"Lencioni R, et al. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. J Hepatol. 2017;66(6):1166\u201372.","journal-title":"J Hepatol"},{"issue":"3","key":"6111_CR26","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1148\/radiol.2020191606","volume":"296","author":"A-L Hermann","year":"2020","unstructured":"Hermann A-L, et al. Relationship of tumor radiation\u2013absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with 90Y in the SARAH study. Radiol. 2020;296(3):673\u201384.","journal-title":"Radiol"},{"key":"6111_CR27","doi-asserted-by":"crossref","unstructured":"Sankhla T, et al. Role of resin microsphere Y90 dosimetry in predicting objective tumor response, survival and treatment related toxicity in surgically unresectable colorectal liver metastasis: a retrospective single institution study. Cancers (Basel).\u00a02021;13(19):4908.","DOI":"10.3390\/cancers13194908"},{"issue":"11","key":"6111_CR28","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1007\/s00259-015-3068-8","volume":"42","author":"C Chiesa","year":"2015","unstructured":"Chiesa C, et al. Radioembolization of hepatocarcinoma with 90Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology. Eur J Nucl Med Mol Imaging. 2015;42(11):1718\u201338.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"6111_CR29","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1007\/s00259-020-05163-5","volume":"48","author":"H Levillain","year":"2021","unstructured":"Levillain H, et al. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur J Nucl Med Mol Imaging. 2021;48(5):1570\u201384.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6111_CR30","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3389\/fonc.2014.00210","volume":"4","author":"M Cremonesi","year":"2014","unstructured":"Cremonesi M, et al. Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective. Front Oncol. 2014;4:210.","journal-title":"Front Oncol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06111-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06111-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06111-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T10:33:56Z","timestamp":1681986836000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06111-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,18]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["6111"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06111-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2272396\/v1","asserted-by":"object"}]},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,18]]},"assertion":[{"value":"14 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Preliminary data from this work was presented at ECIO Conference 2022. This work has not been submitted to any other publications<b>.<\/b>","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}